SCHEMBL29480721

SCHEMBL29480721

CC(c1ccc(-n2cc(-c3ccnc4[nH]cnc34)cn2)nc1)S(C)(=O)=O

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ GRM4 Q14833 3/20 0.38
▸ AURKA O14965 1/20 0.35
▸ AURKB Q96GD4 1/20 0.35
▸ INCENP Q9NQS7 1/20 0.35
▸ TPX2 Q9ULW0 1/20 0.35
▸ EGLN1 Q9GZT9 1/20 0.35
▸ JAK2 O60674 10/20 0.35
▸ JAK1 P23458 8/20 0.35
▸ JAK3 P52333 3/20 0.35
▸ TYK2 P29597 1/20 0.33
▸ GCG P01275 1/20 0.32
▸ CIT O14578 1/20 0.31
▸ KDM4A O75164 1/20 0.31
▸ KDM4B O94953 1/20 0.31
▸ KDM5C P41229 1/20 0.31
▸ KDM5B Q9UGL1 1/20 0.31
▸ MAPK1 P28482 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22736230 1.00 GRM4 (0.38) GRM4AURKAAURKBINCENPTPX2
SCHEMBL29567490 0.87 GCG (0.33) GRM4AURKAAURKBINCENPTPX2
SCHEMBL22716878 0.87 GCG (0.33) GRM4AURKAAURKBINCENPTPX2
SCHEMBL22735741 0.84 EGLN1 (0.39) GRM4AURKAAURKBINCENPTPX2
SCHEMBL29480703 0.84 EGLN1 (0.39) GRM4AURKAAURKBINCENPTPX2
SCHEMBL22735996 0.84 JAK2 (0.32) GRM4AURKAAURKBINCENPTPX2
SCHEMBL29567583 0.84 GRM4 (0.34) GRM4AURKAAURKBINCENPTPX2
SCHEMBL22736261 0.84 GRM4 (0.34) GRM4AURKAAURKBINCENPTPX2
SCHEMBL22736083 0.84 GRM4 (0.35) GRM4AURKAAURKBINCENPTPX2
SCHEMBL29480594 0.84 GRM4 (0.35) GRM4AURKAAURKBINCENPTPX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3976612-A1 NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 MANKIND PHARMA LTD (IN) 2022-04-06 — — EP claimed
US-12516056-B2 Compounds for inhibition of janus kinase 1 MANKIND PHARMA LTD. (IN) 2026-01-06 — — US disclosed
CN-114174294-B Novel compounds for inhibiting JANUS kinase 1 人类制药有限公司 2024-10-25 — — CN disclosed
US-20220235046-A1 NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 MANKIND PHARMA LTD. (IN) 2022-07-28 — — US disclosed
EP-3976612-A1 NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 MANKIND PHARMA LTD (IN) 2022-04-06 — — EP disclosed
CN-114174294-A Novel compounds for inhibiting JANUS kinase 1 人类制药有限公司 2022-03-11 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220235046-A1 NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 JAK1, JAK2, JAK3 GRM4 2623/4885AURKA 222/4885AURKB 325/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback